期刊
MOLECULAR PHARMACEUTICS
卷 9, 期 8, 页码 2168-2179出版社
AMER CHEMICAL SOC
DOI: 10.1021/mp300016p
关键词
HER2; nanoparticles; microSPECT; intratumoral; imaging; ICP-MS; biodistribution; lymph node; pharmacokinetics; antibody
资金
- Canadian Breast Cancer Research Alliance [019374]
- Canadian Institutes of Health Research
- U.S. Army Department of Defense [W81XWH-08-1-0519, P00002]
- University of Toronto
In this study, we have looked at enhancing tumor uptake and intracellular delivery of gold nanoparticles (AuNPs) while reducing the systemic exposure by systematic evaluation of the impact of targeting and route of administration on organ distribution. High-resolution microSPECT/CT imaging was used to track the in vivo fate of In-111-labeled nontargeted and human epidermal growth factor receptor-2 (HER-2) targeted AuNPs following intravenous (i.v.) or intratumoral (i.t.) injection. For i.v. injection, the effects of GdCl3 (for deactivation of macrophages) and nonspecific (anti-CD20) antibody rituximab (for blocking of Fc mediated liver and spleen uptake) were studied. It was found that HER-2 targeting via attachment of trastuzumab paradoxically decreased tumor uptake as a result of faster elimination of the targeted AuNPs from the blood while improving internalization in HER-2-positive tumor cells as compared to nontargeted AuNPs. I.T. injections with HER-2 targeted AuNPs resulted in high tumor retention with low systemic exposure and represents an attractive delivery strategy. Our results provide a strategy for optimizing tumor delivery and quantifying organ distribution of this widely studied class of nanomaterial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据